Therapeutic | Varlilumab |
Target | CD27 |
Heavy Chain | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYDMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGSGNWGFFDYWGQGTLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDRVTITCRASQGISRWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNTYPRTFGQGTKVEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2014 |
INN Year Recommended | 2015 |
Companies Involved | Celldex Therapeutics Inc, Oncothyreon, University of California at San Francisco, University of Virginia |
Conditions Approved | na |
Conditions Active | Malignant melanoma, Solid tumours, Non-Hodgkin's lymphoma, Renal cell carcinoma, Glioma |
Conditions Discontinued | Haematological malignancies, Prostate cancer, Breast cancer, Ovarian cancer |
Notes |